Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-12,507
Closed -$902K 693
2024
Q4
$902K Hold
12,507
﹤0.01% 413
2024
Q3
$1.02M Hold
12,507
﹤0.01% 372
2024
Q2
$929K Buy
12,507
+657
+6% +$49.2K ﹤0.01% 370
2024
Q1
$924K Buy
11,850
+9,650
+439% +$718K ﹤0.01% 382
2023
Q4
$157K Sell
2,200
-514,500
-100% -$35.8M ﹤0.01% 681
2023
Q3
$35.9M Hold
516,700
0.13% 67
2023
Q2
$41.8M Hold
516,700
0.15% 63
2023
Q1
$41.7M Sell
516,700
-66
-0% -$5.31K 0.16% 62
2022
Q4
$38.7M Buy
516,766
+66
+0% +$4.7K 0.14% 67
2022
Q3
$33.3M Hold
516,700
0.14% 69
2022
Q2
$35.8M Sell
516,700
-13,200
-2% -$980K 0.14% 69
2022
Q1
$40.7M Buy
529,900
+93,700
+21% +$6.74M 0.13% 72
2021
Q4
$33.4M Hold
436,200
0.11% 86
2021
Q3
$32.2M Buy
436,200
+2,200
+0.5% +$165K 0.12% 81
2021
Q2
$29M Buy
+434,000
New +$29M 0.11% 86

Other funds holding HOLX

First Manhattan's HOLX Position: Q1 2025 in Review

First Manhattan sold out of Hologic (HOLX) in Q1 2025, closing a stake of 12,507 shares — an estimated $902K sold.

First Manhattan first reported a position in HOLX in Q2 2021 and held it in 15 quarters. The position peaked at $41.8M in Q2 2023. 705 funds tracked by Wall St. Rank hold HOLX as of Q1 2025.

  • First Manhattan reported no remaining Hologic position as of Q1 2025 after selling out during the quarter.
  • First Manhattan sold 12,507 Hologic shares in Q1 2025, an estimated $902K.
  • First Manhattan first reported a position in Hologic in Q2 2021 and held it in 15 quarters.
  • First Manhattan's Hologic position peaked at $41.8M in Q2 2023.
  • 705 funds tracked by Wall St. Rank held Hologic as of Q1 2025.

Based on First Manhattan's 13F filing for Q1 2025, filed 15 May 2025.